Vivos Therapeutics, Inc. announced that the Company presented positive results from a retrospective study with Vivos patients at this year's SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, a joint venture of the American Academy of Sleep Medicine and Sleep Research Society. The presentation highlighted the results of 786 patients who underwent treatment with Vivos' customized, proprietary oral appliances to treat dentofacial abnormalities and/or mild to moderate OSA and snoring in adults. The study participants experienced statistically significant increases in both transpalatal widths (4.5%) and airway volumes (11.1%).

The study results therefore show that use of these devices may result in maxillary and airway expansion, which are critical factors in healthy breathing. Vivos refers to its oral appliance therapy as the Complete Airway Repositioning and/or Expansion (CARE) therapy. Additionally, a subset of 139 patients results showed a decrease in their Apnea Hypopnea Index (AHI – a scale that measures sleep apnea severity) by over 50% in 61.6% of the patients and decreased the overall OSA severity category in 56.8% of the patients.

A core differentiator of Vivos' treatment is that the treatment length is typically 12-24 months, versus modalities such as CPAP or neurostimulation which requires lifetime treatment. This was demonstrated in the study with the pre- and post-treatment measurements taken without the appliance in the mouth.